Novartis AG (0QLR.IL)
| Previous close | 78.76 |
| Open | 79.00 |
| Bid | 77.98 x N/A |
| Ask | 81.52 x N/A |
| Day's range | 78.56 - 80.06 |
| 52-week range | 72.84 - 89.28 |
| Volume | |
| Avg. volume | 1,660,332 |
| Market cap | 172.015B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 8.96 |
| EPS (TTM) | 8.93 |
| Earnings date | N/A |
| Forward dividend & yield | 3.10 (3.75%) |
| Ex-dividend date | 08 Mar 2022 |
| 1y target est | N/A |
- Globe Newswire
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% at Week 52, as evaluated by the HS Clinical Response (HiSCR) measure1 Safety findings were consistent with the well-established safety profile of Cosentyx in its approved indications1 HS is a recurrent skin disease affecting one in 100 people worldwide, causing painful, boil-like a
- Simply Wall St.
Novartis Full Year 2022 Earnings: Misses Expectations
Novartis ( VTX:NOVN ) Full Year 2022 Results Key Financial Results Revenue: US$51.8b (down 2.0% from FY 2021). Net...
- Zacks
Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates
Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.
